Sarah Romano, Chief Financial Officer at Entero Therapeutics, Inc. (ENTO), sold 476 shares at $0.45 ($214) on 2024-10-09, disclosed to the SEC on 2024-10-10.
Open-market sale of $214 ENTO by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| FWBI | SELL | 2024-04-03 | $317 | — | Filing → |
| FWBI | SELL | 2024-03-19 | $6K | — | Filing → |
| FWBI | SELL | 2024-01-17 | $412 | — | Filing → |